Treatment of Crohn’s Disease with Cannabis: An Observational Study
IMAJ – The Israel Medical Association Journal, 2011
Timna Naftali 1, Lihi Bar Lev, Doron Yablecovitch, Elisabeth Half, Fred M Konikoff
1Institute of Gastroenterology and Hepatology, Meir Medical Center, Kfar Saba affiliated with Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
The marijuana plant cannabis is known to have therapeutic effects, including improvement of inflammatory processes. However, no report of patients using cannabis for Crohn’s disease (CD) was ever published. This groundbreaking retrospective observational study in which 30 Crohn’s patients who participated in the study were interviewed, was conducted in collaboration with the Institute of Gastroenterology and Hepatology, Meir Medical Center. was the first to participate IBD cannabis clinical study. The aim of the study was to describe the effects of cannabis use among patients with Crohn’s disease. All patients reported a positive effect on their Crohn’s disease activity and on the symptoms that characterize the disease.
STUDY POPULATION: 30 patients with Crohn’s disease (26 males, mean age 36).
STUDY PRODUCT: Erez
• The average duration of cannabis use was 2.14 years. In 14/30 of the patients, the duration of cannabis use was less than a year.
• Overall improvement – Of the 30 patients, 21 improved significantly after cannabis treatment.
• The Harvey Bradshaw index, an index for assessing the severity of Crohn’s disease, improved from an average of 14 to 7 (P <0.001).
• Decrease in drug use – Consumption of conventional drugs has been significantly reduced.
• 15 patients underwent 19 surgeries in an average period of 9 years before cannabis use, but only 2 required surgery during an average period of 3 years of cannabis use.
• No significant side effects were observed.